CFIA confirms Prince Edward Island's 1st case of dermo, in oysters from Egmont Bay
"This is the first confirmed case of dermo in P.E.I.," the agency said in a news release issued Friday evening. "Dermo does not pose a risk to human health or food safety, but it can cause increased oyster mortality and decreased growth rates."
In a separate email, CFIA also said that tests had confirmed the first cases of both dermo and MSX for the province of Quebec, in oyster samples collected in Chaleur Bay.
It's been eight months since what was considered the first detection of dermo in Canadian waters, in oysters from Spence Cove, about five kilometres west of the Confederation Bridge in New Brunswick.
Dermo disease or Perkinsosis, caused by a parasite called Perkinsus marinus, had previously been detected in Atlantic waters between Mexico and Maine. It affects both cultured and wild American oysters (Crassostrea virginica).
"Outbreaks of Perkinsosis usually occur with warm summer water temperatures above 20 C," a British government fact sheet on the disease says. "Clinical signs may include pale digestive glands, gaping, shrinking of the mantle away from the outer edge of the shell and stunted growth."
The CFIA news release said dermo "does not affect other bivalves in this area, including mussels, scallops or clams."
Already dealing with MSX
News of the positive test results from Egmont Bay will be another blow to the Island's oyster industry, which has been reeling from last July's discovery of MSX, short for multinucleate sphere unknown.
That oyster disease was first detected in samples from P.E.I.'s Bedeque Bay, with more cases confirmed in other areas of the province in the months that followed. Like dermo, it affects only oysters and not the humans eating oysters from waters known to have MSX.
The Canadian Food Inspection Agency says the parasite that causes dermo is easily transmitted among oysters, mostly when they are between one and three years of age.
"Mortality rates are variable but are typically 50 per cent to 75 per cent," the agency says in a factsheet on its website.
CFIA has power to limit movement
In a statement to CBC News last month, the Canadian Food Inspection Agency acknowledged that it had been asked to test P.E.I. oyster samples for dermo, but said it had no results to share at that time.
The agency did go on to outline what would happen if the samples did test positive.
If a product in a PCZ [primary control zone] is deemed to be a potential risk, its movement would be controlled. — Canadian Food Inspection Agency
"To prevent the spread of dermo or any other animal diseases, the CFIA may establish a primary control zone (PCZ) in areas where a disease is suspected to occur," the statement said.
That kind of move would let the agency control how oysters are handled and shipped within and outside the zone.
"For example, if a product in a PCZ is deemed to be a potential risk, its movement would be controlled; this means that a permit from the CFIA would be required to move this product within, through and outside of the PCZ," the statement said.
"Any new PCZs would be posted as soon as possible on CFIA's website. When a new PCZ is put in place, the CFIA also notifies its provincial partners, stakeholders, Indigenous communities and industry through pre-existing communications channels."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
100 years ago, scientists predicted we'd live to 1,000 years old
When Frederick Grant Banting discovered how to isolate insulin from animals in 1921, the young Canadian doctor—a WWI veteran and former farm boy—changed the calculus of diabetes forever. Prior to the 1920s, the disease killed more than 80 percent of preteen diabetic children. Banting's breakthrough replaced the sometimes toxic remedy goat's rue, or Galega officinalis, a flowering plant with glucose-lowering properties derived from guanidine. His discovery came during a wave of medical optimism fueled by new scientific tools and knowledge that were rapidly unlocking the mysteries of human anatomy, disease, and aging. The foundations for this optimism had been building for decades. Germs were first discovered in the 1880s, ushering in the golden age of bacteriology and numerous life-saving vaccines. Vitamins got their name in the early 1900s when London-based Polish biochemist Casimir Funk—one of many scientists seeking cures for common diseases by linking them to vital nutrient deficiencies—combined 'vital' and 'amines.' Rickets led to the discovery of vitamin D, scurvy to vitamin C, and vitamin B was tied to beriberi, a disease that causes weakness, weight loss, confusion, and, in extreme cases, death. Meanwhile, anesthesia transformed surgery from a grisly performing art with low survival rates to more precise procedures conducted in germ-free operating rooms. Bit by bit, medicine appeared to be conquering many of humanity's most pernicious plagues and thereby extending our average lifespan. By July 1925, Popular Science writer John E. Lodge even suggested that humans might soon be able to extend their life expectancy to 1,000 years. 'Thanks to the efforts of science in combatting the ravages of disease, the average span of life is increasing every year,' Lodge wrote. 'Are we to expect, then, that in time science will succeed in prolonging the average life until, like Methuselah, we measure our lives by centuries instead of by years.' Lodge envisioned a world where aging could be halted by replacing worn-out enzymes, transplanting organs, or manipulating an elusive 'vital spark.' Scientists, he claimed, might be on the verge of conquering death itself. A hundred years later, we're still not there, but we continue to chase immortality with the same zest. Just as a century ago, today that quest is fueled not by glamorous breakthroughs—even if history makes it seem so—but by painstaking, collaborative scientific research, yielding fresh medical insights. In place of insulin, vaccines, and vitamins, today we're captivated by gene-editing, cellular reprogramming, and immunotherapy. From biohackers injecting stem cells in search of cellular youth to billionaires like Bryan Johnson leaning on wearable tech for preventative health, blood plasma exchanges, and caloric restriction, the goal of outsmarting death hasn't diminished—the elixirs are just more sophisticated. And yet, we've come a long way in a century. In 1925, the average American lifespan was 58 years; today, it's 78.4 years, according to the US Centers for Disease Control. Such progress might seem meager compared to our grandiose early 20th century expectations, but the trend suggests that by the next century the average American would live to be a centenarian. There's even reason to believe—as there was in 1925—that current promising research might yield treatments as soon as the next few decades that significantly extend our lifespans while improving disease resistance. Consider how researchers in Singapore have extended the lives of mice 25 percent by blocking the protein interleukin-11. Scientists at the University of Rochester have successfully transferred a longevity gene to mice from naked mole rats, which live ten times longer than similar rodents. The gene, known for producing high molecular weight hyaluronic acid, or HMW-HA, extended mouse lives by 4.4% and improved their overall health. The researchers now aim to transfer these benefits to humans. In an ironic twist, a century after Banting's insulin discovery displaced goat's rue, a derivative of the pink-and-white flowering plant is back in favor. Metformin, a biguanide medication, has become one of the leading drugs for managing type 2 diabetes. Like its medieval predecessor, which was used for everything from increasing milk flow in livestock to alleviating plague symptoms, metformin has been similarly used or tested in myriad applications: as an antimalarial drug, influenza treatment, lactation enhancer, arthritis remedy, and cardiovascular medicine. Now, scientists have begun to piece together the mystery of metformin's versatility by mapping how it works at a cellular level. Recent research has shown that it may slow or inhibit cellular changes leading to inflammation and age-related diseases, extending lifespan. The cellular aging story stretches back to the late 19th century. As scientists were discovering germs, developing vaccines, uncovering the link between vital nutrients and common diseases, and improving surgery, evolutionary biologist August Weismann theorized that human cells had replication limits, which explained why the ability to heal diminished with age. By the 1960s, scientists had proven Weismann correct. Today, researchers are learning to halt and reverse cellular aging through reprogramming, an idea first attempted in the 1980s and advanced by Nobel Prize recipient Shinya Yamanaka, who discovered how to revert mature, specialized cells back to their embryonic, or pluripotent state, enabling them to regenerate into new tissue like liver cells or teeth. 100 years ago, the battle for television raged A century ago, suspended monorails were serious mass-transit contenders Why we can't squash the common cold, even after 100 years of studying it 100 years of deep-sea filmmaking and ocean exploration But none of this means we're approaching thousand-year lifespans. Most longevity interventions work only in tightly controlled laboratory settings or short-lived animals. Translating them into humans presents entirely different—and enormously complex—challenges. Even if we managed to double or triple the human lifespan, equally complex social challenges would follow: Who would get access to life-extending therapies? How do we support a society where most people live into their third or fourth century? What psychological toll does such extreme longevity take? The optimism of 1925 wasn't misplaced; it was simply premature. It still might be, but today's longevity researchers are armed with more sophisticated tools and a deeper understanding of biological processes. Whether today's tools and knowledge will finally enable us to defy death remains to be seen. If there's a lesson to draw from the past hundred years, however, it's that life extension is incremental, fragile, and often humbling. We've added decades to average life expectancy, transformed once-fatal diseases into manageable conditions, and dramatically improved the quality of life in later years. That's no small feat—but it's not immortality.
Yahoo
3 hours ago
- Yahoo
Travel nurse company asks court to strike down 'unconstitutional' law designed to nullify contracts
Canadian Health Labs wants the Court of King's Bench to strike down legislation that the province enacted last month, arguing it is unconstitutional, in a bid to avoid any legal or financial penalties over travel nurse contracts between the staffing agency and Vitalité Health Network. In documents filed with the court in Saint John, Canadian Health Labs alleges the Travel Nurses Act represents "unlawful interference" by the legislature of New Brunswick into a "freely negotiated commercial relationship between two commercial entities." It claims the act was "legislated in bad faith and constitutes an abuse of power by the province." The act is "improper, unconstitutional and unconscionable and must be struck down in its entirety," Canadian Health Labs argues in the documents, filed in response to Vitalité's statements of defence and counterclaims to the company's three lawsuits over the contracts. The Ontario-based company has also notified the provincial and federal attorneys general about the "questions of constitutionality raised in this matter," according to the documents. New Brunswick's attorney general declined to comment Friday through Department of Justice and Public Safety spokesperson Jadesola Emmanuel. She cited the matter being before the courts. The Office of the Attorney General of Canada has received notice of a constitutional question related to the provincial Travel Nurses Act, confirmed federal Department of Justice spokesperson Ian McLeod. It will "review in order to determine next steps," he said in an emailed statement. Bill was introduced in March Health Minister Dr. John Dornan introduced the Act Respecting Travel Nurses in March, after Vitalité cancelled the remaining shifts of travel nurses employed by Canadian Health Labs, even though its contract wasn't set to expire until February 2026. "The contract that we signed was not a good contract for New Brunswickers, for taxpayers," Dornan said at the time. It was signed in 2022 in the midst of the COVID-19 pandemic and dire staffing shortages, he said. "We were desperate." Canadian Health Labs charged about $300 an hour per nurse — roughly six times what a local staff nurse earns, Auditor General Paul Martin found in a report last summer. "The contracts with private nursing agencies were not reflective of best practices and did not demonstrate value for money," Martin said. Two days after the legislation was introduced, Canadian Health Labs launched its first lawsuit against Vitalité, alleging breaches of contract and seeking damages. Then, before the legislation was adopted, the company filed two more lawsuits over two other contracts, which were also signed in 2022 but had both expired in 2024. Canadian Health Labs alleged, among other things, that Vitalité deployed fewer "human health resource professionals" than stipulated, failed to pay invoices, and terminated a renewal "unilaterally and improperly." Dornan subsequently appeared before the legislature's standing committee on economic policy to discuss proposed amendments to the bill. Vitalité's lawyers had raised concerns about the expired contracts not being included, Dornan said. So the government decided it would be "prudent, and perhaps safer, to nullify all three contracts," which covered from July 2022 to February 2026 and totalled $98 million, according to the auditor general. Canadian Health Labs alleges the act "has the effect of allowing Vitalité and the province of New Brunswick to not pay its debts, obtain statutorily protected unjust enrichment, not to be held accountable to the various liabilities Vitalité incurred during its commercial relationship with CHL and attempts to shield Vitalité and the province of New Brunswick from judicial oversight and reprimand for its bad faith conduct." The "use of legislation to avoid payment of accounts receivable for services rendered is tantamount to theft," it claims. None of the allegations have been proven in court. Canadian Health Labs goes on to argue that despite the title of the legislation, the Travel Nurses Act "does not address travel nursing in the province." Travel nursing contracts between Vitalité and other companies — Canadian Health Labs' competitors — remain in place and "unaffected," it says. "When the government, acting as a commercial entity, decided it could pay less for the same services, it used its legislative power to deprive CHL of the contracted benefit," according to the documents. The Court of King's Bench of New Brunswick must be free to hear these matters and determine whether the conduct of Vitalité and/or the province of New Brunswick was unlawful, inequitable or deserving of sanction. - Canadian Health Labs In addition, "in anticipation of the legislation, Vitalité made a decision not to terminate the contract which would have triggered damages becoming due and owing on the date of termination." The company argues the government and Vitalité "sought out and induced CHL to enter contractual relationships with Vitalité because of an urgent and desperate need for healthcare providers to keep the hospitals open in New Brunswick," it says. Vitalité "voluntarily agreed to the terms of the contracts with CHL, with the full knowledge and approval of the province." "Without CHL providing nurses, patients would have died," it claims. "The Court of King's Bench of New Brunswick must be free to hear these matters and determine whether the conduct of Vitalité and/or the province of New Brunswick was unlawful, inequitable or deserving of sanction." If the act is not deemed "entirely unconstitutional," Canadian Health Labs argues the legislation does not prevent it from "bringing an action or arbitration for damages." In that alternative scenario, the company seeks a declaration that Vitalité is bound by the terms of the contracts with Canadian Health Labs and that arbitration and/or the lawsuits can proceed on their merits. It also requests that Vitalité's counterclaims be dismissed with costs, and seeks a court order appointing an arbitrator. Vitalité declined to comment, citing the ongoing court proceedings. Canadian Health Labs did not respond to a request for comment.
Yahoo
7 hours ago
- Yahoo
If you're feeling summertime sadness, gloomy weather won't help
Winter and its effects on some people's mood are far behind us, but the same effects can occur in summer, despite the sunshine. With seasonal affective disorder, a depressive episode can coincide with change to a new season — any season. Simon Sherry, a clinical psychologist and a professor of psychology and neuroscience at Dalhousie University, has warned about the side-effects of summer. The change in season, which means a change in our exposure to sunlight, can cause insomnia, reduced appetite and weight loss. This is a mirror of the effects winter weather can have. "There are underlying changes that can happen in our brain," Sherry said. "Our body runs on a circadian rhythm, which is an internal 24-hour clock. And if that cycle, which has a lot to do with sleeping and waking, can get disrupted, then mood problems follow." He points to the daylight savings one-hour time change, which can affect mood. WATCH | How to tell if you're feeling summertime sadness: Michael Mak, a psychiatrist and sleep medicine specialist at the Centre for Addiction and Mental Health in Toronto, said the time when we're taking in sunlight changes by season, which causes the disruption. Taking in sunlight later in the day can make it tougher for people to sleep, which in turn affects mood. "What we want is less light exposure close to bedtime, more light when we wake up in the morning," said Mak, who is also the clinical vice-president of the Canadian Sleep Society. He said 10 to 15 per cent of Canadians can experience a mild form of seasonal affective disorder, and three to five per cent can have a "terribly disabling" degree of symptoms. Mak also said the weather can affect people in similar ways. Consistent rain, which New Brunswick saw over consecutive weekends this spring, can cause symptoms. New Brunswick hasn't seen a precipitation-free weekend since spring started. The capital, Fredericton, saw its first weekend of sun on June 14 and 15. "Having that on a consistent basis means that people are going to be exposed to less natural sunlight and bright light, which stabilizes our internal body clock, makes our sleep better and makes our mood better," said Mak. He said "more rainy days on average" means mood and sleep just get worse. "It just means that you're not able to enjoy the things you usually like. You don't have the opportunity to go out and exercise, which we know is good for mood and good for sleep." For people affected by the season, Mak suggests trying to exercise indoors and consider sunlight exposure therapy. LISTEN | Simons Sherry explains how to spot seasonal affective disorder: An easy exercise is turning on all the lights in your house. There are also special lights that are designed to treat seasonal affective disorder which are available in retail stores. Exposing yourself to light early in the morning can also help with seasonal affective disorder and depression. Sherry said to also consider cognitive behavioural therapy to help change behaviour.
